211372-31-5

Basic information

• Product Name: 7-nitro-1,2,3,4-tetrahydronaphthalen-1-amine
• Synonyms: 7-nitro-1,2,3,4-tetrahydronaphthalen-1-amine
• CAS NO: 211372-31-5
• Molecular Formula: C₁₀H₁₂N₂O₂
• Molecular Weight: 192.21448
• Mol File: 211372-31-5.mol

Chemical Properties

• Boiling Point: 320.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.234±0.06 g/cm3(Predicted)
• PKA: 8.81±0.20(Predicted)
• CAS DataBase Reference: 7-nitro-1,2,3,4-tetrahydronaphthalen-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-nitro-1,2,3,4-tetrahydronaphthalen-1-amine(211372-31-5)
• EPA Substance Registry System: 7-nitro-1,2,3,4-tetrahydronaphthalen-1-amine(211372-31-5)

Safety Data

• Hazardous Substances Data: 211372-31-5(Hazardous Substances Data)

Upstream product

• 40353-34-2 7-nitro-3,4-dihydro-2H-naphthalen-1-one 
• 58490-99-6 7-nitro-3,4-dihydro-2H-naphthalen-1-one oxime 

Downstream Products

• 1170320-97-4 C₁₈H₂₀N₂O₄S 

Relevant articles and documents

Discovery of orexin 2 receptor selective and dual orexin receptor agonists based on the tetralin structure: Switching of receptor selectivity by chirality on the tetralin ring

A novel series of 1-amino-tetralin derivatives were designed and synthesized based on the putative binding mode of the naphthalene-type orexin receptor agonist 5 and their agonist activities against orexin receptors were evaluated. The introduction of N-methyl-(3-methoxyphenyl)acetamide unit onto the 1-amino-tetralin skeleton remarkably enhanced the potency of the agonist. The asymmetric synthesis of 6 revealed that (–)-6 having a (S)-1-amino-tetralin skeleton showed a OX2R selective agonist activity (EC50 = 2.69 nM for OX2R, OX1R/OX2R = 461) yet its enantiomer (R)-(+)-6 showed a potent OX1/2R dual agonist activity (EC50 = 13.5 nM for OX1R, 0.579 nM for OX2R, OX1R/OX2R = 23.3). These results suggested that upward orientation of the amide side chain against the tetralin scaffold (S-configuration) would be selective for OX2R activation, and the downward orientation (R-configuration) would be significant for dual agonist activity. To our best knowledge, there have been no reports thus far that the stereochemistry of one carbon center on the agonist structure regulates the orexin receptor selectivity. Our results would provide important information for the development of OX1R selective agonists.

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

ALPHA-5 BETA-1 INHIBITORS

The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.

Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel

Aryl sulfonamido tetralins based on lead compound 2a were synthesized and evaluated for Kv1.5 inhibitory activity. Several compounds having IC50 values less then 0.1 μM were identified. Kv1.5 inhibitors have the potential to be atrium-selective agents for the treatment of atrial fibrillation.

Synthesis of potent and selective 2-azepanone inhibitors of human tryptase

The serine protease tryptase has been associated with a broad range of allergic and inflammatory diseases and, in particular, has been implicated as a critical mediator of asthma. The inhibition of tryptase therefore has the potential to be a valuable therapy for asthma. The synthesis, employing solution phase parallel methods, and SAR of a series of novel 2-azepanone tryptase inhibitors are presented. A member of this series, 8t, was identified as a potent inhibitor of human tryptase (IC50=38 nM) with selectivity ≤330-fold versus related serine proteases (trypsin, plasmin, uPA, tPA, APC, alpha-thrombin, and FXa).

Sulfonamide-substituted compounds, process for their preparation, their use as a medicament or diagnostic, and a medicament comprising them

Compounds of formula I in which R(1) to R(8) and X have the meanings indicated in the specification, are useful for the production of medicaments having K+ channel-blocking action; in particular for the production of a medicament for the treatment or prophylaxis of stimulated gastric acid secretion; of ulcers of the stomach and of the intestinal region; of reflux esophagitis; of diarrhea; of all types of arrhythmias, including ventricular and supraventricular arrhythmias; and of reentry arrhythmias and for the prophylaxis of sudden heart death as a result of ventricular fibrillation.